Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Net Margin (2018 - 2025)

BioNexus Gene Lab's Net Margin history spans 8 years, with the latest figure at 27.87% for Q3 2025.

  • For Q3 2025, Net Margin rose 2328.0% year-over-year to 27.87%; the TTM value through Sep 2025 reached 24.27%, down 1456.0%, while the annual FY2024 figure was 16.81%, 1010.0% up from the prior year.
  • Net Margin for Q3 2025 was 27.87% at BioNexus Gene Lab, down from 27.26% in the prior quarter.
  • Across five years, Net Margin topped out at 79.55% in Q1 2021 and bottomed at 102.17% in Q3 2023.
  • The 5-year median for Net Margin is 3.01% (2022), against an average of 8.48%.
  • The largest annual shift saw Net Margin tumbled -99486bps in 2021 before it skyrocketed 5103bps in 2024.
  • A 5-year view of Net Margin shows it stood at 3.57% in 2021, then tumbled by -152bps to 1.84% in 2022, then skyrocketed by 939bps to 15.46% in 2023, then crashed by -189bps to 13.8% in 2024, then crashed by -102bps to 27.87% in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Net Margin are 27.87% (Q3 2025), 27.26% (Q2 2025), and 29.17% (Q1 2025).